Taysha Gene Therapies Builds Experienced Executive Leadership Team to Advance Pipeline of Gene Therapies for Monogenic CNS Disease in Both Rare and…

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease, today announced the appointment of its executive leadership team. This group has significant experience in gene therapy drug development and commercialization, and will enable Taysha to build the corporate culture and infrastructure necessary to advance its extensive pipeline of 18 gene therapy programs, with exclusive options to acquire four additional programs from UT Southwestern Gene Therapy Program. In addition, Sukumar Nagendran, M.D., former Chief Medical Officer of AveXis, and Phillip Donenberg, former Chief Financial Officer of AveXis, have joined the companys Board of Directors. Mr. Donenberg will also serve as the companys Audit Committee Chairman.

Joining the Taysha Board is a unique opportunity to contribute to scientific advancements in CNS gene therapy, said Sukumar Nagendran, M.D., Taysha Board of Directors. In partnership with UT Southwestern, Taysha has built an extensive pipeline of gene therapy candidates for life-threatening CNS diseases with significant unmet medical need.

It is a distinct pleasure to be reunited with many of my former AveXis colleagues that enabled the development and successful commercialization of Zolgensma, said Phillip Donenberg, Taysha Board of Directors. I am excited to contribute to Tayshas efforts to deliver therapies with the potential to improve the lives of patients with devastating CNS disease.

Each member of the Taysha leadership team has significant gene therapy expertise, with an unrelenting, patient-first focus guiding their individual areas of focus. Joining RA Session II, Founder, President and CEO of Taysha, on the management team are the following individuals:

From day one, we set out to build a team that has the passion, experience and talent to achieve our mission of eradicating monogenic CNS disease. Today, we are proud to announce a highly experienced team of CNS gene therapy experts, said Mr. Session. We are also pleased Dr. Nagendran and Mr. Donenberg have joined our Board and will contribute their several years of gene therapy expertise. Their experience in building AveXis will be invaluable as we continue to grow and advance several programs into the clinic.

About Taysha Gene Therapies

Taysha Gene Therapies is a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease. We are focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. We were founded in partnership with The University of Texas Southwestern Medical Center, or UT Southwestern, to develop and commercialize transformative gene therapy treatments. Together with UT Southwestern, we are advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. By combining our management teams proven experience in gene therapy drug development and commercialization with UT Southwesterns world-class gene therapy research capabilities, we believe we have created a powerful engine to develop transformative therapies to dramatically improve patients lives. More information is available at http://www.tayshagtx.com.

Excerpt from:

Taysha Gene Therapies Builds Experienced Executive Leadership Team to Advance Pipeline of Gene Therapies for Monogenic CNS Disease in Both Rare and...

Related Post

Comments are closed.